Results 81 to 90 of about 2,846 (189)

Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance

open access: yesEuropean Journal of Neurology, Volume 32, Issue 6, June 2025.
ABSTRACT Background and Objectives Limited data exist on the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and inclisiran among patients with neuromuscular disorders and statin‐induced myotoxicity and/or hepatotoxicity.
Aikaterini Theodorou   +16 more
wiley   +1 more source

Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series [PDF]

open access: gold, 2021
Anji Xiong   +9 more
openalex   +1 more source

Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies [PDF]

open access: hybrid, 2022
Laura Fionda   +16 more
openalex   +1 more source

Miopatías inflamatorias

open access: yesRevista Médica Clínica Las Condes, 2018
RESUMEN: Las miopatías inflamatorias son un grupo heterogéneo de enfermedades adquiridas del músculo estriado esquelético que comparten la injuria muscular inmunomediada como característica común.
Jorge A. Bevilacqua, MD, PhD   +1 more
doaj  

Immune-mediated Necrotizing Myopathy in a Patient with Microscopic Polyangiitis

open access: yesInternal Medicine
We herein report a case of immune-mediated necrotizing myopathy (IMNM) in a patient with microscopic polyangiitis (MPA). A 77-year-old Japanese woman presented with a 2-day history of proximal muscle weakness and myalgia, with elevated serum creatinine kinase (CK) levels.
Umemoto, Daichi   +8 more
openaire   +2 more sources

Alpha‐Synuclein as a Potential Biomarker for Inclusion Body Myositis in Blood and Muscle

open access: yesNeuropathology and Applied Neurobiology, Volume 51, Issue 3, June 2025.
We examined alpha‐synuclein in muscle and serum samples of patients with IBM and other neuromuscular disorders. With the use of immunohistochemistry, we identify alpha‐synuclein muscular reactivity as a complementary diagnostic marker. Serum alpha‐synuclein levels measured by ELISA were not generally altered in IBM but correlated with disease duration ...
Tobias Mayer   +14 more
wiley   +1 more source

From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell Therapy

open access: yesAdvanced Science, Volume 12, Issue 20, May 29, 2025.
This review explores how multi‐omics, visualization technologies, and AI drive CAR‐T therapy from the micro to the macro level, from preclinical studies to clinical applications. The convergence of these approaches provides deeper insight into CAR‐T cell mechanisms, aids in structural optimization, and significantly enhances treatment efficacy and ...
Yuting Gong   +4 more
wiley   +1 more source

AB0871 REMISSION IN ANTI-HMGCR POSITIVE IMMUNE-MEDIATED NECROTIZING MYOPATHY WITHOUT THE USE OF GLUCOCORTICOIDS: A MULTICENTRIC STUDY OF 24 PATIENTS [PDF]

open access: bronze, 2023
D. Martínez-López   +7 more
openalex   +1 more source

Home - About - Disclaimer - Privacy